Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups

Abstract

Inhaled LAMAs are recommended for COPD patients in all GOLD groups (A,B,CD 50% predicted normal) without baseline exacerbation risk. Efficacy of GLY and TIO was analyzed by mean change from baseline at 12 wks for trough FEV 1 (tFEV 1 ), SGRQ score, and TDI score. Of 2599 patients (GLY=1628, TIO=971), 7.6%, 52.6%, 2.8% and 37.0% were classed in GOLD groups A, B, C and D respectively. GLY showed significant improvement in tFEV 1 in patients in all groups after 12 treatment wks compared with baseline; TIO showed significant improvement only in BD p=0.0036)]. GLY significantly improved dyspnea in patients in all GOLD groups, similar to TIO. GLY and TIO showed similar and significant improvement in SGRQ only in GOLD groups B&D. In conclusion, GLY and TIO significantly improved dyspnea (in all GOLD groups) and health status (GOLD Groups B&D). GLY provided significant improvement in tFEV 1 in patients in all GOLD groups, while TIO showed statistically significant improvement in tFEV 1 only in patients in group B&D. GOLD 2015.